Abstract Details

Read the abstract and find the presentation below

Full text and presentation details

G - Cell Therapies -> Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)

Long-term Follow-up of Subjects With Diabetes 2 Type Treatment with ex vivo Gene Therapy

Type: Oral Abstract Session

Presentation Details
Session Title: Late-Breaking Abstracts I
Location: Salon H
Start Time: 5/17/2022 9:30
End Time: 5/17/2022 9:45

Metabolic syndrome and finally diabetes 2 type (DT2) as a result of progressive obesity, insulin resistance, abnormal cholesterol or triglyceride levels are newfound problems in the current endocrinology. As reported by the International Diabetes Federation, in the entire world 382 million of adults (8.3%) are living with diabetes; the number is estimated to increase to 592 million in the next 20 years. Human of peripheral blood mesenchymal stem (MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (DT2), but the results of autologous auto-MSC administration in DT2 patients are contradictory. The purpose of this study was to test the hypothesis that autologous MSC administration in DT2 patient is safe and that the efficacy of the treatment is dependent on the quality of the autologous MSC population and administration routes and is to focus on mitochondrial dysfunction. Materials and methods Mesenchymal stem cell separated of peripheral blood from diabetes 2 type patients was collected in the context of a clinical protocol authorized by the local Ethics Committee of Ukraine Association of Biobank (Ukraine), with a license from the Ministry of Health of Ukraine 04/10/2018 №1813 and 27/03/2019 №1231 by the national competent authority for biobank cord blood, cell and, tissue therapy. The study population (n = 96) was represented by diabetic patients from SI «ZIGUS NAMSU» in Kharkiv, Ukraine, and healthy volunteers. DT2 patients were enrolled, randomly assigned (1treated patients, and the efficacy was evaluated based on the absolute changes in the hemoglobin A1c, fasting blood glucose, and C-poated in 30 DT2 patients. Patients were divided into two groups: group I consisted of patients with diabetes 2 type (DT2), group II - patients with DT2 complicated course of NASH (DT2 + NASH). The control group consisted of 25 conditionally healthy persons (men and women) of the same age. Conclusion: DT2 duration directly altered the proliferation rate of auto-MSCs, abrogated the glycolysis and mitochondria respiration of MSCs, and induced the accumulation of mitochondria DNA mutation. In the modern scientific space, various directions have been proposed in the diagnosis of metabolic syndrome and the treatment of D2T.

Svitlana Gramatiuk1, Julia Ivanova2

1Ukraine Association of Biobank, Kharkiv, Ukraine,2Kharkiv National Medical University, Kharkiv, Ukraine
 S. Gramatiuk: None.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.